Turning rare diseases into efficient targets with AI

BenevolentBio's CMO, Dr Patrick Keohane, says the industry is on the cusp of an artificial intelligence (AI) revolution… Medical research is entering a period of rapid transformation, driven by the explosion of scientific data, rapid advances in artificial intelligence (AI), and the development of extremely powerful computers. This convergence enables researchers to access enormous and diverse datasets to rapidly form and test scientific hypotheses. It is disrupting the way we identify, validate, and transform scientific concepts into potential Healthcare solutions – ultimately revolutionising the scientific process. AI enables access and the more effective use of existing information for the discovery and development of better drugs at a speed previously unimagined. This is helping to meet the high demand from society to provide better medicines at a reasonable cost, but also influencing how we are looking to treat rarer forms of disease.